MCM
TBIO

Marathon Capital Management’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Marathon Capital Management’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-143,275
Closed -$2.64M – 196
2020
Q4 		$2.64M Buy
143,275
+75,200
+110% +$1.35M 0.78% 27
2020
Q3 		$926K Buy
+68,075
New +$1.05M 0.34% 49

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

Marathon Capital Management's TBIO Position: Q1 2021 in Review

Marathon Capital Management sold out of Translate Bio, Inc. Common Stock (TBIO) in Q1 2021, closing a stake of 143,275 shares — an estimated $2.64M sold.

Marathon Capital Management first reported a position in TBIO in Q3 2020 and held it in 2 quarters. The position peaked at $2.64M in Q4 2020. 146 funds tracked by Wall St. Rank hold TBIO as of Q1 2021.

  • Marathon Capital Management reported no remaining Translate Bio, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Marathon Capital Management sold 143,275 Translate Bio, Inc. Common Stock shares in Q1 2021, an estimated $2.64M.
  • Marathon Capital Management first reported a position in Translate Bio, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Marathon Capital Management's Translate Bio, Inc. Common Stock position peaked at $2.64M in Q4 2020.
  • 146 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q1 2021.

Based on Marathon Capital Management's 13F filing for Q1 2021, filed 14 May 2021.